Integration of intratumoral RASSF10 expression and tumor-associated macrophages into the established clinical indicators better predicts the prognosis of clear cell renal cell carcinoma patients

References

• Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. doi:10.1038/nrdp.2017.9.
   PubMed Web of Science ®Google Scholar
• Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–11. doi:10.1016/S0140-6736(09)60229-4.
   PubMed Web of Science ®Google Scholar
• Li JK, Chen C, Liu JY, Shi JZ, Liu SP, Liu B, Wu DS, Fang ZY, Bao Y, Jiang MM, et al. Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPR3 and activating p38-MAPK signaling. Mol Cancer. 2017;16(1):111. doi:10.1186/s12943-017-0681-0.
   PubMed Web of Science ®Google Scholar
• Parker WP, Cheville JC, Frank I, Zaid HB, Lohse CM, Boorjian SA, Leibovich BC, Thompson RH. Application of the stage, size, grade, and necrosis (SSIGN) score for clear cell renal cellcarcinoma in contemporary patients. Eur Urol. 2017;71(4):665–673. doi:10.1016/j.eururo.2016.05.034.
   PubMed Web of Science ®Google Scholar
• Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507–524. doi:10.3322/caac.21411.
   PubMed Web of Science ®Google Scholar
• Wang M, Li X, Zhang J, Yang Q, Chen W, Jin W, Huang YR, Yang R, Gao WQ. AHNAK2 is a novel prognostic marker and oncogenic protein for clear cell renal cell carcinoma. Theranostics. 2017;7(5):1100–1113. doi:10.7150/thno.18198.
   PubMed Web of Science ®Google Scholar
• Hakimi AA, Chen YB, Wren J, Gonen M, Abdel-Wahab O, Heguy A, Liu H, Takeda S, Tickoo SK, Reuter VE, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol. 2013;63(5):848–854. doi:10.1016/j.eururo.2012.09.005.
   PubMed Web of Science ®Google Scholar
• Wang C, Li Y, Chu CM, Zhang XM, Ma J, Huang H, Wang YN, Hong TY, Zhang J, Pan XW, et al. Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinoma. EbioMedicine. 2019;39:255–264. doi:10.1016/j.ebiom.2018.12.011.
   PubMed Web of Science ®Google Scholar
• Giraldo NA, Becht E, Vano Y, Petitprez F, Lacroix L, Validire P, Sanchez-Salas R, Ingels A, Oudard S, Moatti A, et al. Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin Cancer Res. 2017;23(15):4416–4428. doi:10.1158/1078-0432.CCR-16-2848.
   PubMed Web of Science ®Google Scholar
• Bakhtyar N, Wong N, Kapoor A, Cutz JC, Hill B, Ghert M, Tang D. Clear cell renal cell carcinoma induces fibroblast-mediated production of stromal periostin. Eur J Cancer. 2013;49(16):3537–3546. doi:10.1016/j.ejca.2013.06.032.
   PubMed Web of Science ®Google Scholar
• Chittezhath M, Dhillon MK, Lim JY, Laoui D, Shalova IN, Teo YL, Chen J, Kamaraj R, Raman L, Lum J, et al. Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. Immunity. 2014;41(5):815–829. doi:10.1016/j.immuni.2014.09.014.
   PubMed Web of Science ®Google Scholar
• Fu Q, Xu L, Wang Y, Jiang Q, Liu Z, Zhang J, Zhou Q, Zeng H, Tong S, Wang T, et al. Tumor-associated macrophage-derived interleukin-23 interlinks kidney cancer glutamine addiction with immune evasion. Eur Urol. 2019;75(5):752–763. doi:10.1016/j.eururo.2018.09.030.
   PubMed Web of Science ®Google Scholar
• Komohara Y, Hasita H, Ohnishi K, Fujiwara Y, Suzu S, Eto M, Takeya M. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci. 2011;102(7):1424–1431. doi:10.1111/j.1349-7006.2011.01945.x.
   PubMed Web of Science ®Google Scholar
• Han X, Dong Q, Wu J, Luo Y, Rong X, Han Q, Zheng X, Wang E. RASSF10 suppresses lung cancer proliferation and invasion by decreasing the level of phosphorylated LRP6. Mol Carcinog. 2019;58(7):1168–1180. doi:10.1002/mc.23000.
   PubMed Web of Science ®Google Scholar
• Liu W, Wang J, Wang L, Qian C, Qian Y, Xuan H, Zhuo W, Li X, Yu J, Si J. Ras-association domain family 10 acts as a novel tumor suppressor through modulating MMP2 in hepatocarcinoma. Oncogenesis. 2016;5(6):e237. doi:10.1038/oncsis.2016.24.
   PubMedGoogle Scholar
• Richter AM, Walesch SK, Dammann RH. Aberrant promoter methylation of the tumour suppressor RASSF10 and its growth inhibitory function in breast cancer. Cancers (Basel). 2016;8:3. doi:10.3390/cancers8030026.
   Web of Science ®Google Scholar
• Lu D, Ma J, Zhan Q, Li Y, Qin J, Guo M. Epigenetic silencing of RASSF10 promotes tumor growth in esophageal squamous cell carcinoma. Discov Med. 2014;17:169–178.
   PubMed Web of Science ®Google Scholar
• Jin Y, Cao B, Zhang M, Zhan Q, Herman JG, Yu M, Guo M. RASSF10 suppresses hepatocellular carcinoma growth by activating P53 signaling and methylation of RASSF10 is a docetaxel resistant marker. Genes Cancer. 2015;6(5–6):231–240. doi:10.18632/genesandcancer.67.
   PubMedGoogle Scholar
• Li X, Liang Q, Liu W, Zhang N, Xu L, Zhang X, Zhang J, Sung JJ, Yu J. Ras association domain family member 10 suppresses gastric cancer growth by cooperating with GSTP1 to regulate JNK/c-Jun/AP-1 pathway. Oncogene. 2016;35(19):2453–2464. doi:10.1038/onc.2015.300.
   PubMed Web of Science ®Google Scholar
• Dong T, Zhang M, Dong Y, Herman JG, van Engeland M, Zhong G, Guo M. Methylation of RASSF10 promotes cell proliferation and serves as a docetaxel resistant marker in human breast cancer. Discov Med. 2015;20:261–271.
   PubMed Web of Science ®Google Scholar
• Deng J, Liang H, Ying G, Li H, Xie X, Yu J, Fan D, Hao X. Methylation of ras association domain protein 10 (RASSF10) promoter negative association with the survival of gastric cancer. Am J Cancer Res. 2014;4:916–923.
   PubMed Web of Science ®Google Scholar
• Younesian S, Shahkarami S, Ghaffari P, Alizadeh S, Mehrasa R, Ghavamzadeh A, Ghaffari SH. DNA hypermethylation of tumor suppressor genes RASSF6 and RASSF10 as independent prognostic factors in adult acute lymphoblastic leukemia. Leuk Res. 2017;61:33–38. doi:10.1016/j.leukres.2017.08.016.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol. 2005;2:416–422.
   PubMedGoogle Scholar
• Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105. doi:10.1016/j.eururo.2016.02.029.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Lu QJ, Li CG, Wang XY, Jiang L, Huang L, Wang C, Chen HZ. PRMT1 regulates the tumour-initiating properties of esophageal squamous cell carcinoma through histone H4 arginine methylation coupled with transcriptional activation. Cell Death Dis. 2019;10(5):359. doi:10.1038/s41419-019-1595-0.
   PubMedGoogle Scholar
• Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Xie H, Fu Q, Dai B, Ye D, Identification XJ. Validation of stromal immunotype predict survival and benefit from adjuvant chemotherapy in patients with muscle-invasive bladder cancer. Clin Cancer Res. 2018;24(13):3069–3078. doi:10.1158/1078-0432.CCR-17-2687.
   PubMed Web of Science ®Google Scholar
• Wang C, Yan FH, Zhang JJ, Huang H, Cui QS, Dong W, Zhang WW, Zhao Y, Chen HZ, Zhao TJ. OV6+ cancer stem cells drive esophageal squamous cell carcinoma progression through ATG7-dependent β-catenin stabilization. Cancer Lett. 2017;391:100–113. doi:10.1016/j.canlet.2017.01.026.
   PubMed Web of Science ®Google Scholar
• Graham J, Dudani S, Heng DYC. Prognostication in kidney cancer: recent advances and future directions. J Clin Oncol. 2018:JCO2018790147. doi:10.1200/JCO.2018.79.0147.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Liu L, Xia Y, Qi Y, Chen Y, Chen L, Zhang P, Kong Y, Qu Y, Wang Z, et al. Tumor infiltrating mast cells determine oncogenic HIF-2α-conferred immune evasion in clear cell renal cell carcinoma. Cancer Immunol Immunother. 2019;68(5):731–741. doi:10.1007/s00262-019-02314-y.
   PubMed Web of Science ®Google Scholar
• Hill VK, Underhill-Day N, Krex D, Robel K, Sangan CB, Summersgill HR, Morris M, Gentle D, Chalmers AD, Maher ER, et al. Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene. 2011;30(8):978–989. doi:10.1038/onc.2010.471.
   PubMed Web of Science ®Google Scholar
• Ma J, Zhang S, Hu Y, Li X, Yuan F, Sun D, Wang L, Zhang F, Chen G, Cui P. Decreased expression of RASSF10 correlates with poor prognosis in patients with colorectal cancer. Medicine (Baltimore). 2017;96(42):e7011. doi:10.1097/MD.0000000000007011.
   PubMed Web of Science ®Google Scholar
• Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, Griffiths M, Chalmers AD, Maher ER, Latif F. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer. 2009;8:42. doi:10.1186/1476-4598-8-42.
   PubMed Web of Science ®Google Scholar
• Dansranjavin T, Wagenlehner F, Gattenloehner S, Steger K, Weidner W, Dammann R, Schagdarsurengin U. Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma. Prostate. 2012;72(14):1550–1558. doi:10.1002/pros.22510.
   PubMed Web of Science ®Google Scholar
• Andersen R, Westergaard MCW, Kjeldsen JW, Müller A, Pedersen NW, Hadrup SR, Ö M, Seliger B, Kromann-Andersen B, Hasselager T, et al. T-cell responses in the microenvironment of primary renal cell carcinoma-implications for adoptive cell therapy. Cancer Immunol Res. 2018;6(2):222–235. doi:10.1158/2326-6066.CIR-17-0467.
   PubMed Web of Science ®Google Scholar
• Kawashima A, Kanazawa T, Goto K, Matsumoto M, Morimoto-Okazawa A, Iwahori K, Ujike T, Nagahara A, Fujita K, Uemura M, et al. Immunological classification of renal cell carcinoma patients based on phenotypic analysis of immune check-point molecules. Cancer Immunol Immunother. 2018;67(1):113–125. doi:10.1007/s00262-017-2060-5.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang E, Long J, Hu Z, Peng J, Liu L, Tang F, Li L, Ouyang Y, Zeng Z. Immune infiltration in renal cell carcinoma. Cancer Sci. 2019;110(5):1564–1572. doi:10.1111/cas.13996.
   PubMed Web of Science ®Google Scholar
• Komohara Y, Morita T, Annan DA, Horlad H, Ohnishi K, Yamada S, Nakayama T, Kitada S, Suzu S, Kinoshita I, et al. The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas. Cancer Immunol Res. 2015;3(9):999–1007. doi:10.1158/2326-6066.CIR-14-0156.
   PubMed Web of Science ®Google Scholar
• Dannenmann SR, Thielicke J, Stöckli M, Matter C, von Boehmer L, Cecconi V, Hermanns T, Hefermehl L, Schraml P, Moch H, et al. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology. 2013;2(3):e23562. doi:10.4161/onci.23562.
   PubMed Web of Science ®Google Scholar
• Xie J, Chen Y, Meng F, Shu T, Liu Y, Zhang L, Zhang ZX. Study on the relationship between the RASSF10 gene and the biological behavior of hepatocellular carcinoma cells. Eur Rev Med Pharmacol Sci. 2017;21:3576–3580.
   PubMed Web of Science ®Google Scholar